Vortioxetine hydrobromide is indicated for the treatment of major depressive disorder. The product is in the α-crystalline form, which avoids patent protection of the original research drug. Once approved, it can be immediately launched for sale. Fokam Pharmaceutical's vortioxetine hydrobromide has a CDE registration status of "A".